Loading clinical trials...
Loading clinical trials...
An Open-label Extension Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Subjects With DSM-5 Schizophrenia
Conditions
Interventions
Xanomeline and Trospium Chloride Capsules
Locations
44
United States
Pillar Clinical Research
Bentonville, Arkansas, United States
Woodland International Research Group
Little Rock, Arkansas, United States
Advanced Research Center, Inc.
Anaheim, California, United States
Advanced Research Center Inc
Bellflower, California, United States
CITrials
Bellflower, California, United States
Proscience Research Group
Culver City, California, United States
Start Date
February 1, 2021
Primary Completion Date
October 3, 2023
Completion Date
October 3, 2023
Last Updated
October 28, 2024
NCT06894212
NCT04226898
NCT05240976
NCT06745479
NCT05304767
NCT07455929
Lead Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions